Aidan G. Gilmartin

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 280 citations · Full text

Medicine, Oncology, Pharmacology +8

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo et al. · Proceedings of the National Academy of Sciences · 2010 · 254 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Jeffrey R. Jackson, Aidan G. Gilmartin, Christina S. Imburgia et al. · PubMed · 2000 · 233 citations

Life Sciences, Cell Biology, Molecular Biology +17

Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction

Aidan G. Gilmartin, Thomas Faitg, Mark C. Richter et al. · Nature Chemical Biology · 2014 · 208 citations

Life Sciences, Biochemistry, Molecular Biology +14